To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome (NCT06840496)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome
🩺 Plain-English Summary (8th-Grade Level)
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Who can join: Review the eligibility criteria below.
Location: Biomed Testing Facility # BIO-01-85012 — Phoenix, Arizona
Age range: 5 Years to 20 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Biomed Testing Facility # BIO-01-85012 — Phoenix, Arizona
- Biomed Testing Facility # BIO-05-92093 — La Jolla, California
- Biomed Testing Facility # BIO-04-90095 — Los Angeles, California
- Biomed Testing Facility # BIO-03-95817 — Sacramento, California
- Biomed Testing Facility # BIO-02-94104 — San Francisco, California
- Biomed Testing Facility #BIO-06-80042 — Aurora, Colorado
- Biomed Testing Facility #BIO-07-33606 — Tampa, Florida
- Biomed Testing Facility #BIO-08-60612 — Chicago, Illinois
- Maryland Locations Biomed Testing Facility #BIO-9-21205 — Baltimore, Maryland
- Biomed Testing Facility #BIO-10-02115 — Boston, Massachusetts
- Biomed Testing Facility #BIO-13-10467 — The Bronx, New York
- Biomed Testing Facility #BIO-17-19104 — Philadelphia, Pennsylvania
- Biomed Testing Facility #BIO-19-77030 — Houston, Texas
- Biomed Testing Facility #BIO-20-98105 — Seattle, Washington
- Biomed Research Unit-BIO-23-NSW 2050 — Camperdown, New South Wales
- Biomed Research Unit-BIO-24-NSW-4101 — South Brisbane, Queensland
- Biomed Research Unit-BIO-21-VIC-3084 — Heidelberg West, Victoria
- Biomed Research Unit- BIO-22-VIC 3010 — Parkville, Victoria
📞 Contact the Study Coordinator
Phone: (800) 824-5135
Email: research@biomedind.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rett Syndrome
- Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) — Chicago, Illinois
- Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome — Birmingham, Alabama
- Technology-supported Motor Rehabilitation for People With Rett Syndrome — Bethesda, Maryland
- A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) — Duarte, California
- A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome — Birmingham, Alabama
- A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome — Toronto, Ontario
Explore by condition: All Rett Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.